Combination of Renal Angioplasty and Angiotensin-converting-enzyme Inhibitor Can Reduce Proteinuria in Patients with Bilateral Renal Artery Disease

Recent large clinical trials failed to show clear benefits of percutaneous transluminal renal angioplasty (PTRA) as compared with medical therapy on patients with renal artery stenosis. It was also reported that proteinuria is an adverse prognostic factor after PTRA, and PTRA is less effective in pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Toda, Hironobu, A. Uchida, Haruhito, Nakamura, Kazufumi, Takeuchi, Hidemi, Kinomura, Masaru, Nakagawa, Koji, Watanabe, Atsuyuki, Miyoshi, Toru, Nishii, Nobuhiro, Morita, Hiroshi, Wada, Jun, Ito, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6663532/
https://www.ncbi.nlm.nih.gov/pubmed/30799351
http://dx.doi.org/10.2169/internalmedicine.2076-18
Descripción
Sumario:Recent large clinical trials failed to show clear benefits of percutaneous transluminal renal angioplasty (PTRA) as compared with medical therapy on patients with renal artery stenosis. It was also reported that proteinuria is an adverse prognostic factor after PTRA, and PTRA is less effective in patients with overt proteinuria. From the renoprotective point of view, to reduce proteinuria after PTRA is an important therapeutic goal in patients with renal artery stenosis with overt proteinuria. We hereby describe two patients successfully treated by combination therapy with PTRA and administration of angiotensin-converting enzyme (ACE) inhibitor for bilateral renal artery disease with overt proteinuria.

Ejemplares similares